Innovations + Investments in Healthcare Summit 2015

Novartis

NovartisNovartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 102,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis RSS Channel

Title Filter      Display #  
# Article Title
1 Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients
2 Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches
3 Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.
4 Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
5 Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
6 Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors
7 Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group
8 FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
9 Novartis announces completion of transactions with GSK
10 Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma
11 Novartis Pharmaceuticals announces a joint investment company with Qualcomm
12 Novartis collaborates with Intellia Therapeutics and Caribou Biosciences
13 Novartis Foundation symposium showcases sustainable healthcare interventions
14 New data on the global economic impact and burden of preventable blindness and vision impairment
15 Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC
16 Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
17 Novartis provides drug candidate compounds to TB Alliance
18 Novartis maintained strong innovation momentum in second quarter
19 Novartis to license Google "smart lens" technology
20 Novartis reinforces its leadership in research with new global guidelines for Investigator Initiated Trials (IITs)
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]